The therapeutic use of Giane 35 is primarily used to help address androgen-dependent symptoms in women of reproductive age. It is an antiandrogen-estrogen combination relevant when supportive symptom management is appropriate for persistent manifestations of male hormone excess.

Giane 35 is commonly used across conditions where the patient experiences severe or persistent acne, seborrhea, and hirsutism (unwanted hair growth). This is typically applied in contexts where initial, less specialized treatments have been unsuccessful in managing pronounced symptoms that create noticeable interference with daily stability. The treatment helps address symptoms related to heightened physiological activity.

Therapeutic Benefits

Giane 35 contributes to the establishment of more regular and predictable menstrual cycles and provides support that helps ease the overall symptom burden. When used for these indications, it is also considered relevant for providing simultaneous cycle control and pregnancy prevention. The primary therapeutic benefit assists with maintaining functional stability and may include support for clearer skin and a reduction of unwanted hair.

---

Quick Fact: Symptomatic Support

Giane 35 is used for managing visible symptoms related to male hormone excess, specifically severe acne and moderate hirsutism. It is applied in scenarios where additional management of discomfort is required when symptoms prove unresponsive to standard care.

---

Regulatory References

1. European Medicines Agency referral conclusion

Giane 35 (Cyproterone/Ethinyl Estradiol) is strictly authorized for use only in a specific subpopulation of women and is defined by an extensive list of non-eligibility criteria, or contraindications.

Eligibility and Exclusion Status

Category	Official Regulatory Status/Statement
Populations Allowed	Women of reproductive age with moderate to severe acne and/or hirsutism (unwanted hair growth) who have failed initial treatments (topical or systemic antibiotics) [1.1, 1.6].
Age-Related	Only indicated after menarche and not indicated after menopause [1.6].
Pregnancy/Lactation	Contraindicated during pregnancy (known or suspected) [1.6]. Contraindicated/Not recommended during lactation [1.6].
Strict Restriction	Must not be used in combination with any other hormonal contraceptive [1.6].
Key Contraindications	History or presence of venous or arterial thromboembolic disease (blood clots, stroke, heart attack) [1.6, 3.2]; severe hepatic disease or liver tumours [1.6]; breast cancer [1.6]; migraine with focal neurological symptoms [1.6].
Comorbidity Exclusion	Women with severe diabetes with vascular complications or other multiple risk factors for thrombosis must not use this medicine [1.6, 3.2].

The official documents define eligibility by establishing a second-line indication and mandating the exclusion of individuals with significant vascular or neoplastic risk factors, which are the primary determinants of non-eligibility.

Interactions with other medicines and products

Official regulatory documentation requires strict attention to be paid to drug interactions that may alter the concentration of the hormonal components or increase toxicity risks.

Contraindicated Combinations

This product must not be used in combination with other hormonal contraceptives because co-administration leads to an overdose of estrogen, increasing the risk of thromboembolism.

It is also contraindicated for use with direct-acting antiviral (DAA) regimens for Hepatitis C Virus (HCV) that contain specific combinations, such as ombitasvir/paritaprevir/ritonavir and dasabuvir, or glecaprevir/pibrentasvir, due to the potential for significant increases in liver enzyme (ALT) elevations.

Reduction of Efficacy and Increased Exposure

Concomitant use with certain medicines may reduce the efficacy of Giane 35 by accelerating the metabolism of the estrogen component. These enzyme-inducing agents include specific anticonvulsants (e.g., phenobarbital, phenytoin, carbamazepine) and the anti-tuberculosis medicine rifampicin. Other antibiotics (e.g., ampicillin, griseofulvin) may also reduce effectiveness, which could necessitate the use of supplementary non-hormonal contraception.

Conversely, drugs that inhibit the metabolism of the hormonal components or compete for protein binding, such as Vitamin C (ascorbic acid) and certain antifungals, may increase exposure and potentially raise the risk of side effects.

Effect on Other Drugs

This product may affect the metabolism or activity of other medicines. Specifically, the regulatory label notes that it may reduce the effectiveness of anticoagulants and require an adjustment in the dosage of antidiabetic or hypoglycemic agents.

How Giane 35 Works

The mechanism operates through three coordinated domains of action, targeting both the central production and the peripheral effects of androgens.

The active ingredient, Cyproterone Acetate, engages in competitive antagonism at the Androgen Receptor (AR) in end-organ cells, such as those in hair follicles and sebaceous glands. This molecular blockade prevents natural androgens from activating the receptor and initiating the associated signaling cascade, thereby contributing to the reduction in androgen-sensitive tissue response.

Simultaneously, Ethinyl Estradiol initiates a systemic mechanism by stimulating hepatocytes to produce high levels of Sex Hormone Binding Globulin (SHBG). This increased SHBG tightly binds circulating testosterone in the plasma, reducing the concentration of free, biologically active androgen. This systemic ligand deprivation is complemented by the combination's negative feedback on the Hypothalamic–Pituitary–Ovarian (HPO) axis.

This central regulation suppresses the release of gonadotropins (LH and FSH), which prevents the maturation of ovarian follicles and inhibits ovulation. The reduced gonadotropin levels also lower ovarian androgen synthesis. The resulting inhibition of ovulation establishes a controlled pattern of endometrial proliferation and shedding.

Administration Scope

Giane 35 is administered through the oral route as a fixed-dose combination tablet containing 2 mg of cyproterone acetate and 0.035 mg of ethinyl estradiol. The dosing schedule is a standardized cyclic regimen: one tablet must be taken daily for 21 consecutive days, followed by a 7-day tablet-free interval. To maintain the intended hormonal pattern, the tablet should be taken at about the same time every day, a requirement that is independent of mealtimes, as it may be taken with or without food.

Use-Context and Duration

A key procedural condition is the instruction that Giane 35 must not be used concomitantly with any other hormonal contraceptive. The frequency pattern is a consistent daily intake across the 21-day active phase. Instructions for handling a missed dose specify that if the delay is less than 12 hours, the dose should be taken immediately. If the tablet is missed by more than 12 hours, the medicine's contraceptive protection is considered reduced, necessitating the use of additional non-hormonal contraception for the following seven days.

The course duration is sustained, as treatment is typically continued for an additional 3 to 4 cycles after the user’s condition has stabilized. Treatment should be evaluated periodically, and use in patients under 18 is not generally recommended for this specific set of indications.

Research Evidence / Overview of Studies

Mechanism of Action

Research examined the drug's properties in laboratory settings. Studies explored the observed relationship between drug exposure and changes in symptoms associated with androgenization, such as acne and excessive hair growth (hirsutism). Giane 35 is a combination of two hormonal compounds: cyproterone acetate, which acts as an antiandrogen and progestin, and ethinylestradiol, which acts as an estrogen. Research suggests the antiandrogenic effect is achieved primarily by blocking androgen receptors.

---

Efficacy and Symptom Management

Studies have evaluated the experimental use of the drug in managing androgen-dependent skin conditions, specifically severe acne and hirsutism, particularly when other treatments (such as oral antibiotics) have been unsuccessful. These studies primarily focus on objective measures like lesion counts, hirsutism scores, and subjective reports of symptom improvement.

Key Findings from Primary Research

• Acne: Trials have consistently reported improvements in severe acne and seborrhea, with results becoming apparent after approximately 3 to 4 treatment cycles and improving further over longer use (e.g., 6–12 months).
• Hirsutism: Research has shown a reduction in hirsutism scores, indicating a decrease in excessive hair growth in women.
• Hormonal Parameters: Studies investigating the components of Giane 35 report associated changes in hormonal markers, including increases in serum Sex Hormone Binding Globulin (SHBG) and reductions in free testosterone levels.

---

Safety Profile

Long-term studies have examined the safety profile in adults, with a focus on adverse events common to hormonal contraceptives.

• Adverse Events: The most frequently reported adverse events (occurring in more than 5% of participants) were characterized by researchers as low in severity and temporary, including headache, nausea, breast tenderness, and breakthrough bleeding.
• Risk: The risk of venous thromboembolism (VTE) associated with this combination of hormones is a known consideration, and is reported to be generally consistent with other combined oral contraceptives.

---

Conclusion of Evidence

The available research represents one potential area of inquiry, supporting the studied use of Giane 35 for specific androgen-dependent conditions. Evidence remains limited regarding specific long-term outcomes beyond 36 months, and its use is typically reserved for cases where other therapies have failed.

Common questions about Giane 35 (FAQ)

Q: Why is Giane 35 sometimes prescribed for skin issues like acne?

Official documents describe that Giane 35 works by targeting the hormonal causes of certain skin conditions. The medicine contains an antiandrogen component that works by blocking androgen receptors. Additionally, the estrogen component is described as increasing Sex Hormone Binding Globulin (SHBG), which in turn reduces free-circulating androgens in the blood.

Q: When does Giane 35 usually start to show effects for acne?

Studies and official information indicate that improvements in acne may be reported as early as three months after starting use. Further improvements are typically observed during subsequent cycles of treatment. Treatment is generally continued for a set number of cycles after the condition has stabilized.

Q: Do antibiotics like amoxicillin interact with Giane 35?

Official regulatory text notes that some antibiotics may reduce the effectiveness of this medicine by accelerating the way the hormones are broken down in the body. The official documents suggest consulting a healthcare provider about the need for supplementary non-hormonal contraception if a drug interaction is a risk.

Q: Does Giane 35 affect libido?

Official safety documents list changes in sexual desire as an uncommon adverse reaction associated with Giane 35. The effect is classified as uncommon in official safety documents.

Q: Is it normal to have breakthrough bleeding when starting Giane 35?

Intermenstrual bleeding, often called breakthrough bleeding, has been reported as an expected adverse event in clinical studies, particularly during the initial phase of use as the body adjusts to the hormonal regimen. If breakthrough bleeding persists, users are advised to consult their prescribing health professional.

Q: Why do some regulatory agencies require Giane 35 to be used as a 'second-line' treatment?

The official indications for this medicine require that it should only be used when conditions such as severe acne are unresponsive to other initial treatments. These initial treatments typically include topical therapy and oral antibiotic courses. This medicine is reserved for cases that have failed these other options.

Q: Is Giane 35 suitable for women over 35?

Official labeling states that the medicine is only indicated for use after menarche (the start of menstruation). Warnings and precautions for this class of medicine relate the risk of venous thromboembolism (VTE) to advanced age, which is a key consideration for all combination hormonal medicines.

Q: Is Giane 35 a type of anti-androgen?

Official documents describe Giane 35 as an Antiandrogen-Estrogen combination medicine. The cyproterone acetate component within the tablet is specifically classified as a potent antiandrogen, which means the compound acts against the effects of androgens in the body.

Q: Does Giane 35 change how long or heavy my period is?

The medicine is designed to provide comprehensive hormonal regulation, and research notes that one benefit is cycle control. The estrogen component in the pill is included to help avoid menstrual cycle disturbances. These actions result in a controlled pattern of endometrial shedding.

Q: Can Giane 35 make you gain weight?

Weight increase is listed in official regulatory documents as a common adverse reaction associated with the use of this medicine. As with any adverse reaction, users may wish to consult their health professional if they have concerns.

Q: How common are mood changes or depression while using Giane 35?

Depressive mood is listed in official documents as a common adverse reaction associated with Giane 35. The reported frequency is comparable to other combination hormonal medicines.

Q: Are there any common over-the-counter pain relievers that interact with Giane 35?

The regulatory label notes that the medicine may modify the action of other drugs. Specifically, it has been noted that patients on chronic therapy with medicines like ASA (Aspirin) may require a dosage increase while using Giane 35.

Q: Can Giane 35 be used by women who smoke (general eligibility question)?

Official regulatory text notes that the risk of heart attack when using combined estrogen/progestogen medicines is increased for heavy smokers. Official information notes that smoking is a key risk factor related to this class of medication.

Q: Is there long-term data available on the safety of Giane 35?

Long-term therapy (up to 36 months) with this combination of hormones has been examined in clinical research. Regulatory documents emphasize that the use of Giane 35 is typically reviewed periodically by a healthcare professional.

Q: Has Giane 35 been studied for its effect on hair loss?

Official therapeutic indications for Giane 35 include the treatment of androgenetic alopecia (hair loss) in women. This is because the antiandrogenic component works to reduce the effects of male hormones that can contribute to this condition.

Q: What happens if you stop taking Giane 35 suddenly?

Studies on discontinuation have indicated a potential for hyperandrogenic skin symptoms, such as acne and hirsutism, to reappear following treatment cessation.

Q: Does Giane 35 increase the risk of blood clots?

Official warnings state that the medicine is associated with an increased risk of venous thromboembolism (VTE) compared with non-use. Official information notes that this risk is greatest during the initial period of use or upon restarting the medicine following an interval.

Q: Is Giane 35 the same as the drug Diane-35?

The product monograph for DIANE-35 confirms that it contains the same fixed-dose combination of 2 mg cyproterone acetate and 0.035 mg ethinyl estradiol. This suggests they share the same fixed-dose combination of active ingredients.

Q: Are there different brand names for the same Giane 35 drug composition?

Official drug lists confirm that multiple brand names exist for this specific combination and dosage of cyproterone acetate and ethinyl estradiol.

Q: Can Giane 35 cause migraines to become more frequent?

Migraine is listed in regulatory documents as an uncommon adverse reaction associated with the medicine. Furthermore, the medicine is strictly contraindicated (must not be used) in women who have migraine with focal neurological symptoms.

Q: What type of research evidence is available for Giane 35's use in moderate acne?

The official indication for Giane 35 includes the treatment of moderate to severe acne related to androgen-sensitivity. This means that clinical trials and evidence support its use for patients whose acne falls within this severity range.

Q: Is the main purpose of Giane 35 to regulate hormones?

Official documents describe the medicine’s primary purpose as modulating the effects of androgens and providing comprehensive hormonal regulation. This dual action helps mitigate the physical manifestations of high androgen sensitivity while establishing cycle control.

Q: Do research studies compare Giane 35 to placebo?

Yes, clinical research has included comparisons of this medicine against placebo in some studies. These comparisons helped evaluate the medicine’s effectiveness on certain measures, suchs as the reduction of acne lesions.

Q: What does the term 'anti-androgenic' mean in the context of Giane 35?

The term 'anti-androgenic' describes the component that works against the effects of androgens, which are hormones. This component specifically works by blocking androgen receptors on cells and reducing the synthesis of androgens in the body.

Q: Does Giane 35 affect cholesterol levels?

Official documents report that a trend to increased plasma cholesterol and triglyceride levels was observed during long-term therapy. This is a potential metabolic effect observed in studies.

How to Store and Dispose of Giane 35

Official Storage Requirements

Regulatory documents mandate specific conditions to preserve the stability of Giane 35 tablets. The medicine must be stored at a temperature below 30 C in a dry place and be protected from light.

To ensure product integrity, the tablets must remain in their original package and should not be used if the packaging appears torn or tampered with. It is a mandatory requirement to keep Giane 35 out of the sight and reach of children.

Disposal Instructions

Unused or expired Giane 35 tablets should not be discarded with household garbage or disposed of in wastewater, such as flushing down the toilet. Instead, disposal instructions require the product to be returned to a pharmacist or an approved take-back program for safe handling and environmental protection. The medicine must not be used after the expiry date printed on the packaging.